KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $2.1 million.

  • Aquestive Therapeutics' Other Non-Current Liabilities rose 122.97% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 122.97%. This contributed to the annual value of $2.4 million for FY2024, which is 1879.96% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Other Non-Current Liabilities is $2.1 million, which was up 122.97% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Other Non-Current Liabilities ranged from a high of $2.5 million in Q4 2021 and a low of $1.8 million during Q1 2021
  • Its 5-year average for Other Non-Current Liabilities is $2.1 million, with a median of $2.0 million in 2024.
  • Examining YoY changes over the last 5 years, Aquestive Therapeutics' Other Non-Current Liabilities showed a top increase of 3440.68% in 2022 and a maximum decrease of 1814.89% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Other Non-Current Liabilities (Quarter) stood at $2.5 million in 2021, then decreased by 18.15% to $2.0 million in 2022, then dropped by 0.88% to $2.0 million in 2023, then increased by 18.8% to $2.4 million in 2024, then fell by 14.07% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.1 million for Q2 2025, and $2.2 million during Q1 2025.